Clinical Trials Sponsored by Fina Biotech

Total 1969 results

Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Peripheral Neuropathy, Chemotherapy-induced

United States
Astellas Pharma Global Development, Inc.
Janssen Biotech, Inc.

Completed

A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects

Healthy Subjects | Bioavailability of ASP015K | Pharmacokinetics of ASP015K | Food Effect of ASP015K

United States
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery

Hemostasis, Surgical
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Neoplasms | Cancer | Anemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Terminated

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Myelodysplastic Syndromes | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)

Anemia
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children

Influenza

China
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine

Prevention | Pandemic Influenza
The Alvin and Lois Lapidus Cancer Institute
Ortho Biotech Products, L.P.

Unknown

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

Lymphoma, Non-Hodgkin | Diffuse Large B Cell Lymphoma

United States
HoHo Biotech
Tri-Service General Hospital; Taoyuan Armed Forces General Hospital

Recruiting

To Evaluate the Efficacy of Oral Molecular Hydrogen Supplement in Patients With Chronic Diseases

Chronic Disease | Chronic Inflammation

Taiwan
Institute of Hematology & Blood Diseases Hospital
Hangzhou Qihan Biotech Co.,Ltd.

Not yet recruiting

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Minimal Residual Disease | AML, Adult

China
MEI HENG
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies

Neoplasms | Neoplasms by Site | Hematologic Diseases | Hematologic Neoplasms

China
Beijing Tsinghua Chang Gung Hospital
Beijing DCTY® Biotech Co.,Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma

Recurrent Glioblastoma
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Not yet recruiting

Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital...
Nanjing Legend Biotech Co.

Active, not recruiting

A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia

China
Sinovac Biotech Co., Ltd
Liaoning Center for Disease Control and Prevention

Active, not recruiting

Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old

Hepatitis A

China
Weijia Fang, MD
Nanjing Blue Shield Biotech Co.,Ltd

Completed

Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer

Ovarian Cancer

China
Xiamen Amoytop Biotech Co., Ltd.
First Affiliated Hospital of Zhejiang University

Completed

A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease

Renal Anemia of Chronic Kidney Disease

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Lymphoma, B-Cell

China
Sinovac Biotech Co., Ltd
Guangdong Center for Disease Prevention and Control

Completed

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines

Hand, Foot and Mouth Disease

China
Taipei Medical University WanFang Hospital
Hi-Q Marine Biotech International, Ltd.

Unknown

Supplementation of Brown Seaweed on Insulin Resistance of NAFLD Patients With Pre- or Type 2-Diabetes

Type II Diabetes

Taiwan
The Sixth Affiliated Hospital of Wenzhou Medical...
Zhejiang Qixin Biotech

Unknown

Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors

Nectin4-positive Advanced Malignant Solid Tumor

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Withdrawn

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Refractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic Leukemia

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia

Acute Myeloid Leukemia | Acute Leukemia | Acute Leukemia in Relapse | Relapsed or Refractory Acute Leukemia

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

China
University of Texas Southwestern Medical Center
Ortho Biotech Clinical Affairs, L.L.C.

Withdrawn

Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer

Ovarian Cancer

United States
Tianjin Medical University Cancer Institute and...
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients (NSCLC)

Non-small Cell Lung Cancer

China
isRed Pharma & Biotech Research Corporation
Yung Shin Pharmaceutical Ind. Co., Ltd.

Unknown

A Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product

Healthy Adult Subjects

Taiwan
Astellas Pharma Global Development, Inc.
Janssen Biotech, Inc.

Completed

A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

Healthy Subjects | Pharmacokinetics of ASP015K

United States
Astellas Pharma Global Development, Inc.
Janssen Biotech, Inc.

Completed

Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin

Healthy Subjects | Pharmacokinetics of ASP015K

United States
Bharat Biotech International Limited
PATH; Ministry of Science and Technology, India

Unknown

A Phase III Clinical Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E (ROTAVAC)

Viral Gastroenteritis Due to Rotavirus

India
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.

Anemia | Chronic Kidney Disease
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Completed

PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy

Neoplasms | Anemia
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine

Prevention | Pandemic Influenza | Pandemic Influenza Vaccine

China
NanOlogy, LLC
US Biotest, Inc.

Available

Expanded Access to NanoPac
NanOlogy, LLC
US Biotest, Inc.

Completed

Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Locally Advanced Pancreatic Adenocarcinoma

United States
NanOlogy, LLC
US Biotest, Inc.

Terminated

Trial of NanoPac Focal Therapy for Prostate Cancer

Urogenital Neoplasms | Genital Neoplasms, Male | Prostate Cancer | Prostate Adenocarcinoma | Prostatic Neoplasm | Localized Cancer | Prostate Cancer Adenocarcinoma

United States
NanOlogy, LLC
US Biotest, Inc.

Withdrawn

Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

Kidney Cancer | Renal Cell Carcinoma | Renal Cell Cancer | Adenocarcinoma of Kidney | Adenocarcinoma, Renal
University of Miami
Biotics, Inc.

Completed

Vitamin D's Effect on Physical Performance in the Elderly

Family Member

United States
Tianjin Medical University Cancer Institute and...
Nanjing Legend Biotech Co.

Not yet recruiting

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | B-Cell Non-Hodgkin Lymphoma-Refractory

China
ProDa BioTech, LLC
University of Alabama at Birmingham; Georgia State University

Recruiting

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Ductal Carcinoma

United States
Institute of Hematology & Blood Diseases Hospital
Hangzhou Qihan Biotech Co.,Ltd.

Recruiting

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

AML, Adult

China
State Key Laboratory of Respiratory Disease
CAS Lamvac Biotech Co., Ltd.

Recruiting

Plasmodium Immunotherapy for Lung Cancer

Lung Cancer, Nonsmall Cell

China
Sinovac Biotech Co., Ltd
Jiangxi Center for Disease Control and Prevention

Active, not recruiting

Immunogenicity of After Primary Immunization and Booster Immunization of sIPV

Polio

China
Chengdu Kanghong Biotech Co., Ltd.
Guangzhou Keli Medical Research Co., Ltd.

Enrolling by invitation

Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data

Retinopathy of Prematurity

China
The Third Xiangya Hospital of Central South University
SANSURE BIOTECH INC.

Unknown

Multicenter Study on Detection Strategy of Infectious Diseases in Blood Transfusion

Infectious Disease Screening

China
Astellas Pharma Global Development, Inc.
Janssen Biotech, Inc.

Completed

A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

Arthritis, Rheumatoid

United States, Belgium, Bulgaria, Colombia, Czechia, Hungary, Mexico, Poland
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Anemia

Clinical Trials Sponsored by Fina Biotech

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations